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Role of purinergic signaling in 
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Excessive neutrophilic inflammation contributes to brain pathology and adverse outcome in 
pneumococcal meningitis (PM). Recently, we identified the NLRP3 inflammasome/interleukin (IL)-1β 
pathway as a key driver of inflammation in PM. A critical membrane receptor for NLRP3 inflammasome 
activation is the ATP-activated P2 purinoceptor (P2R) P2X7. Thus, we hypothesized involvement of 
ATP and P2Rs in PM. The functional role of ATP was investigated in a mouse meningitis model using 
P2R antagonists. Brain expression of P2Rs was assessed by RT-PCR. ATP levels were determined in 
murine CSF and cell culture experiments. Treatment with the P2R antagonists suramin or brilliant blue 
G did not have any impact on disease course. This lack of effect might be attributed to meningitis-
associated down-regulation of brain P2R expression and/or a drop of cerebrospinal fluid (CSF) ATP, as 
demonstrated by RT-PCR and ATP analyses. Supplemental cell culture experiments suggest that the 
reduction in CSF ATP is, at least partly, due to ATP hydrolysis by ectonucleotidases of neutrophils and 
macrophages. In conclusion, this study suggests that ATP-P2R signaling is only of minor or even no 
significance in PM. This may be explained by down-regulation of P2R expression and decreased CSF ATP 
levels.
Bacterial meningitis is among the worldwide top ten causes of mortality from infectious diseases, and many of 
the survivors show significant long-term neurologic disabilities1. The most frequent etiologic agent in Europe 
and Northern America is Streptococcus (S.) pneumoniae, causing more than two-third of all meningitis cases2. 
Pneumococcal infection of the leptomeninges generates a powerful inflammatory reaction which contributes 
essentially to meningitis-associated brain damage3–5. This reaction is initiated when resident immune cells sense 
the presence of pneumococci by recognizing pathogen-associated molecular patterns (PAMPs) via a set of pat-
tern recognition receptors (PRRs), namely Toll-like receptors (TLR)5,6. TLR engagement then results in myeloid 
differentiation primary response protein (MyD) 88-dependent production of a vast array of pro-inflammatory 
cytokines and chemokines7–9. As a consequence, blood-borne neutrophils are recruited in huge numbers into the 
leptomeninges. Activated neutrophils emit numerous cytotoxic factors which aim to kill the bacteria, but can also 
cause damage to neighbouring host cells.
Data from patients10 and animal experiments8,11 have provided evidence that excessive production of the 
cytokine interleukin (IL-) 1β plays a key role in the pathogenesis of PM. Consistently, we found that mice defi-
cient in caspase-1 which converts pro-IL-1 β to its mature, biologically active form showed a strongly diminished 
inflammatory host response to pneumococci in the CSF7. We further demonstrated that lack of the inflammas-
ome components ASC or NLRP3 that are centrally involved in caspase-1 activation also resulted in reduced brain 
inflammation in murine PM9. Moreover, using differentiated human THP-1 cells, we observed that the release of 
IL-β 1 was timely associated with an increase in both caspase-1 activity and extracellular ATP (eATP) concentra-
tions, and inhibition of ATP signaling by treatment with periodate-oxidized ATP attenuated IL-1β generation9. 
Accordingly, human and murine neutrophils were recently demonstrated to secrete IL-1β in a NLRP3 
inflammasome-dependent manner in response to eATP and during S. pneumoniae corneal infection12.
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ATP is normally present in every living cell at relatively high amounts, whereas its extracellular concentrations 
are considerably lower13,14. During diverse pathologic conditions, notably inflammation, ischemia, and trauma, 
ATP can be released from its intracellular storage pools into the extracellular space15. The inside-outside translo-
cation of ATP can occur via two separate mechanisms. Inflammatory cells can secrete ATP via pannexin or con-
nexin hemichannels13,16. In addition, ATP can be passively liberated from dying cells following nuclear and cell 
membrane disintegration13,16. Once in the extracellular space, ATP can behave as a “danger signal” and directly 
activate two families of plasma membrane receptors named P2 receptors (P2R), P2X and P2Y receptors13,16. 
Members of both families of P2R have been implicated in the modulation of immune responses by a variety of 
mechanisms including regulation of neutrophil functions, such as adherence, chemotaxis, phagocytosis, and oxi-
dative burst, as well as macrophage function, such as non-directed migration, phagocytic clearance of apoptotic 
cells, and cytokine release (particularly of IL-1β )13,14,16. P2R signaling is terminated by diffusion of the ligand from 
its binding site and its subsequent phosphohydrolysis which is under the control of specific ectonucleotidases 
called CD39 and CD7313,14,16.
The role of P2R signaling in bacterial infections of the brain and its coverings, however, is widely unknown. 
Studies in experimental models have merely demonstrated that cortical ATP levels were decreased by about a 
quarter, and this loss of (intracellular) ATP was positively correlated with the extent of neuronal injury17,18. As 
mentioned before, recent studies proposed a role of eATP in macrophage and neutrophil response during both 
pneumococcal corneal infection and in vitro9,12. This study aimed to assess the functional relevance of eATP in 
pneumococcal meningitis (PM) which represents a common and very serious form of brain infection.
Results
P2R antagonism inhibits S. pneumoniae - induced macrophage activation. Recent data from our 
group suggested an involvement of eATP in NLRP3-inflammasome–dependent IL-1β release by differentiated 
human THP-1 cells upon exposure to S. pneumoniae19. To confirm this hypothesis, we stimulated bone mar-
row-derived macrophages (BMDM) with D39 pneumococci in the absence or presence of suramin or brilliant 
blue G (BBG), both of which are well-known P2R receptor antagonists, albeit with significant differences in 
receptor subtype specificity. Suramin as well as BBG inhibited IL-1β secretion upon pneumococcal challenge in a 
concentration-dependent manner (Fig. 1A). Both substances also prevented pneumococci-induced production 
of IL-6 (Fig. 1B).
P2R antagonism has no effect on the development of PM. To test the functional significance of 
P2R signaling in pneumococcal meningitis, mice were treated before infection with suramin or BBG, and exam-
ined 16 h later. BBG is a commonly used P2X7R antagonist capable of crossing the intact blood-brain barrier 
(BBB)20,21. The non-selective P2R antagonist suramin, however, was reported to penetrate only poorly into the 
brain under normal conditions22,23. The BBB is usually broken down in PM so the delivery of suramin across the 
BBB may not be an important problem. Nevertheless, in order to be sure not to miss any effect of the drug due to 
limited bioavailability, suramin was administered via the intracisternal (i.c.) route in an additional experimental 
group. Neither pre-treatment with suramin (irrespective of the application route) nor BBG had any potential 
impact on the development of meningitis. At 16 h after infection, the number of leukocytes in the cerebrospinal 
fluid (CSF) was comparable between mice that received the P2R antagonists and those that were injected with the 
vehicle (water, Fig. 2A). Accordingly, CSF concentrations of IL-1β were not altered by treatment with suramin 
or BBG (Fig. 2B). Compatible with the lack of effect on brain inflammation, there were no between-group dif-
ferences in the degree of intracranial complications like the rise in ICP or the magnitude of intracerebral hem-
orrhages (data not shown). Correspondingly, the clinical status assessed 16 h post infection, as well as the loss in 
body weight (Fig. 2C,D) and temperature (data not shown) were similar between treated and control mice. In 
addition, treatment with suramin or BBG did not result in significant alterations of pneumococcal titres in the 
brain and blood (Fig. 2E,F).
Brain P2R expression and CSF ATP levels decreased substantially during PM. In order to find 
possible explanations for the lacking effect of P2R antagonism in vivo, we next investigated the expression of P2Rs 
in murine brains during the course of PM. As shown in Fig. 3, PM led to substantial down-regulation of most P2R 
subtypes including P2X1, P2X4, P2X7, P2Y4, P2Y12, and P2Y14. The expression of the P2Y2 subtype remained 
constant at a low level throughout the observation period, whereas a mild increase in P2Y6 mRNA expression was 
detectable in advanced stages of the disease.
Apart from P2R expression, the extracellular nucleotide concentration is an essential determinant for the 
extent to which purinergic signaling can contribute to immune responses. Thus, we also measured ATP levels in 
murine CSF samples withdrawn before and at different time points after pneumococcal infection. CSF ATP levels 
markedly dropped during the course of the disease and became nearly undetectable 16 h and 40 h after pneumo-
coccal inoculation (Fig. 4).
Macrophage and neutrophil CD39 seems to contribute to eATP decrease. Since macrophages and 
neutrophils are major players of the inflammatory response in PM, we questioned whether these cells have a role 
in the observed decrease in ATP concentrations in the CSF. In order to address this aspect, we grew live S. pneu-
moniae D39 in the absence or presence of murine BMN or BMDM in aCSF substituted with 10 nM ATP (which 
represents the ATP concentration in normal rodent CSF24). After 30 min and 120 min of culture, aCSF samples 
were taken and used for ATP determinations. Pneumococcal outgrowth within cell-free aCSF was accompa-
nied by a time-dependent increase in ATP levels. This increase was attenuated and even completely prevented 
by the presence of BMN and BMDM, respectively (Fig. 5). The ATP-degrading activity of BMN and BMDM 
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could be – at least in part – blocked by treatment with ARL67156, hinting at a possible role of CD39 in the 
meningitis-associated decrease in CSF ATP.
In order to exclude that BMN and/or BMDM indirectly affect eATP concentrations by limiting pneumococcal 
outgrowth within the aCSF, we also determined pneumococcal titres at the end of each experiment by culturing 
serial dilutions of aCSF samples on agar plates. There were no differences in pneumococcal outgrowth, irrespec-
tive of whether they were grown in the absence or presence of BMN or BMDM (e.g., pneumococcal titres in the 
absence and presence of BMDM after 30 min of culturing, 7.14 ± 0.08 vs. 7.06 ± 0.14 log10 cfu/ml, and 120 min of 
culturing, 7.67 ± 0.07 vs. 7.71 ± 0.12 log10 cfu/ml, respectively; not significant).
Discussion
Excessive neutrophilic inflammation contributes to brain pathology and consequently an unfavorable outcome 
of PM3,4,6. Among the host factors that drive inflammation are IL-1 cytokine family members. Concentrations 
of IL-1β are elevated in CSF samples from patients with bacterial meningitis and correlate significantly with 
CSF leukocyte counts and clinical outcome10. In animals, i.c. injection of recombinant IL-1β was sufficient to 
induce meningitis25. Moreover, pharmacologic and genetic blockade of IL-1β production or signaling attenuated 
meningeal inflammation and improved the clinical course of PM7–9,26. Recent studies demonstrated a central role 
of eATP in S. pneumoniae-induced-1L-β release by THP-1 macrophages and neutrophils in vitro as well as in 
murine corneal infection9,12. Therefore, we hypothesized that eATP may act as a modulator of inflammation and 
tissue damage in PM. Surprisingly, pharmacologic interference with eATP signaling did neither influence the host 
immune response nor the clinical course of PM in mice, although this approach proved to be efficient in prevent-
ing cytokine production and cell death in cultured BMDM upon exposure to pneumococci. Our in vivo findings 
contrast to numerous reports that have provided evidence for eATP as an autocrine and paracrine signaling mole-
cule that trigger pro-inflammatory immune responses by activating cell surface P2R (for review see refs 16, 27 and 
28). For instance, in models of acute neurodegeneration including cerebral ischemia, traumatic brain or spinal 
cord injury, subarachnoid hemorrhage, and seizures, pharmacologically or genetically induced ATP hydrolysis 
Figure 1. P2R antagonism modulates murine macrophage activation upon exposure to Streptococcus 
pneumoniae in vitro. To elucidate the role of P2R signaling in S. pneumoniae-induced macrophage activation, 
murine bone marrow-derived macrophages (BMDM) were exposed to D39 pneumococci (107 cfu/ml) in the 
absence or presence of suramin or BBG. Six hours later, medium samples were withdrawn and analysed for 
the presence of IL-1β (a) and IL-6 (b) using commercially available assay kits. All experiments were - at least - 
carried out twice in triplicates. Data are given as means ± SD. *P < 0.05, compared to S. pneumoniae -challenged 
macrophages, #P < 0.05, compared to S. pneumoniae -challenged macrophages treated with the lower doses of 
the respective inhibitor, using ANOVA and Student-Newman-Keuls test for post hoc analysis.
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and/or P2R (above all P2X7) inhibition was shown to inhibit microglial activation, neutrophil inflammation, and 
cytokine expression20,21,29–31. This reduction in neuroinflammation was usually accompanied by neuroprotection 
and better outcome30,32–34. Similarly, purinergic signaling through P2R was demonstrated to have immunostim-
ulant effects in diverse bacterial infection models. For example, local nucleotide application elevated the levels of 
cytokines/chemokines and neutrophils in peritoneal lavage fluid in mouse Escherichia coli peritonitis models35,36 
(33;34). P2R deficiencies, in turn, were associated with blunted innate immune responses in experimental models 
of lung infection (e.g., with Pseudomonas aeruginosa37), sepsis induced by cecal ligation and puncture38, as well 
Figure 2. P2R antagonism has no effect on the disease course of PM. Mice were treated with suramin (given 
either by the intraperitoneal or the intracisternal route; 20 mg/kg body weight or brain weight, respectively; 
n = 11 for each group), BBG (applied intraperitoneally; 50 mg/kg body weight; n = 11), or vehicle (untreated 
infected mice; n = 11). In an additional experimental group, mice were injected intracisternally with water 
(vehicle) 2 hours prior to infection. Pneumococcal meningitis was induced by intracisternal injection of S. 
pneumoniae (strain D39). Sixteen hours later, animals were evaluated. (a) The number of white blood cells 
(WBC) in the CSF was comparable between mice that received P2R antagonists and those that were injected 
with vehicle. (b) The meningitis-induced rise in intracranial pressure (ICP) was also not altered by treatment 
with P2R antagonists. (c,d) There were also no between-group differences in the clinical status and in the 
reduction of body weight. (e,f) Moreover, pneumococcal outgrowth in the brain (as determined by cerebellar 
titres) and blood was not affected by pre-treatment with P2R antagonists. Data are given as means ± SD. 
*P < 0.05, compared to infected animals, using ANOVA and Student-Newman-Keuls post-hoc test.
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as septic encephalopathy39. Moreover, pharmacologic inhibition and/or genetic ablation of enzymes that degrade 
nucleotides like ATP dramatically enhanced inflammation in pneumococcal pneumonia40 (while treatment with 
ATP-degrading enzymes attenuated the immune response after intratracheal administration of LPS41 and in 
Figure 3. Brain P2R expression during PM. Expression of P2R subtypes in brain tissue collected from mice 
before, 4 hours (h), 16 h, and 40 h after the induction of PM (n = 4 each group). Relative expression of different 
P2 receptors (a–h) were analysed in comparison to the housekeeping gene β 2 microglobulin using quantitative 
RT-PCR. Data are given as means ± SD. *P < 0.05, compared to uninfected controls, #P < 0.05, compared to 
4 h post infection, $P < 0.5, compared to 40 h post infection, using unpaired Student’s t test and Bonferroni 
correction for multiple comparisons.
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Figure 4. CSF ATP concentration during the course of PM. ATP concentrations were measured in CSF 
samples withdrawn from mice (n = 4 each group) before and at defined time points after infection with S. 
pneumoniae using a commercially available bioluminescence kit. Data are given as means ± SD. *P < 0.05, 
compared to PBS-injected controls (Con; n = 4), using unpaired Student’s t test and Bonferroni correction for 
multiple comparisons.
Figure 5. ATP catabolism by BMN and BMDM in vitro. S. pneumoniae was grown in the absence or 
presence of murine BMDM (a) or BMN (b) (100,000 cells per well) in artificial CSF to which ATP was added 
at its physiological concentration. After 30 min (grey bars) and 120 min (black bars) of culture, artificial CSF 
samples were taken and used for ATP determinations using a commercially available bioluminescence kit. 
When indicated, the ectonucleotidase inhibitor ARL67156 (1 mM) was given to the culture medium prior to 
the addition of S. pneumoniae and murine immune cells. All experiments were – at least - carried out twice 
in triplicates. Data are given as means ± SD. **P < 0.001 und *P < 0.01, compared to respective group, using 
ANOVA and Student-Newman-Keuls post-hoc test.
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experimental polymicrobial sepsis42. These ATP driven innate immune response can both protect and harm the 
host, depending on whether the benefits (namely efficient bacterial clearance) outweigh the adverse consequences 
(namely bystander tissue injury). According to this thesis, blockade of ATP degradation led to enhanced lethality 
in experimental pneumococcal pneumonia by exaggerating harmful effects of inflammation40. Correspondingly, 
P2R (namely P2X7) signaling was shown to promote inflammation-induced brain injury during septic encepha-
lopathy39 whereas its definite role in polymicrobial sepsis is still controversial, with some studies reporting dele-
terious action38 and others reporting the opposite42. Favorable effects of ATP and P2R signaling were also seen in 
Escherichia coli peritonitis35,36 and bacterial lung infections, e.g., with Pseudomonas aeruginosa37. These positive 
effects were related to an enhancement of bacterial clearance. Thus, the current literature indicates that eATP 
acts as key regulator of sterile and microbial inflammatory processes16,27,28. To our best knowledge, there are only 
a handful of papers reporting no effect of ATP and/or P2R signaling on acute neurodegenerative or infectious 
diseases. For example, deletion of P2X7 receptor was found neither to affect ischemic or excitotoxic neuronal 
cell death43 nor to contribute to control of pulmonary Mycobacterium tuberculosis infection44. This could be due 
to a publication bias favoring studies with positive results or, which is more likely, to the fact that eATP and P2R 
signaling plays a nearly universal role in shaping immune response to injury and infection. Thus, we considered 
our results to be unexpected and looked for possible explanations. It is now well established that purinergic sig-
naling is a tightly regulated process and may depend, amongst others, on extracellular levels of nucleotides and 
the expression pattern of P2R and P1R16,28,45. We therefore analyzed brain mRNA expression levels of P2R as well 
as ATP concentration in CSF samples from mice with PM. PM was associated with a robust down-regulation 
of most P2R subtypes. In addition, CSF ATP became nearly undetectable during the course of the disease. The 
dramatic decline in eATP levels and P2R expression represent a likely explanation for the lack of any effect of P2R 
antagonism in PM and also for the striking differences in this aspect between PM and other acute neurological 
disorders like ischemia, brain injury or septic encephalopathy.
Recently, George and colleagues46 demonstrated that E. coli LPS can increase the extracellular catabolism of 
ATP into adenosine through ectonucleotidases by cultured microglial cells. In order to evaluate whether locally 
present immune cells contribute to the drop of CSF ATP levels in PM, we next cultured live S. pneumoniae 
in the absence or presence of murine BMN or BMDM in aCSF to which ATP was added at its physiological 
concentration24. In the absence of BMN or BMDM, pneumococcal outgrowth led to a substantial increase in 
eATP levels. This rise was undetectable in the presence of BMN or BMDM, but (at least in part) reversible by the 
co-administration of ARL67156. Thus, our findings are in line with that of George and colleagues46, and suggest 
a contribution of CD39 to the meningitis-associated decrease in CSF ATP.
Although purinergic signaling is essential for NLRP3 inflammasome-dependent IL-1β secretion from mac-
rophages in vitro, is seems to be dispensable under in vivo conditions, namely in pneumococcal meningitis. To 
date, a two-signal model is proposed for NLRP3 inflammasome activation. In this model, the first signal ( = prim-
ing signal) is provided by microbial or endogenous molecules (e.g., pneumococcal PAMPs) that induce NLRP3 
and pro-IL-1β expression through activation of the transcription factor NF-κ B. The second signal (= activating 
signal) is triggered by a plethora of stimuli, such as ATP, particulate matters, or pore-forming toxins47–49. In pneu-
mococcal meningitis, the pore-forming toxin pneumolysin may substantially contribute to NLRP3 inflammas-
ome activation, as evidenced, for example, by significantly lower brain IL-1β concentrations in mice infected with 
pneumolysin-deficient pneumococci than in those infected with the respective wild type strain9.
In conclusion, the present study showed that P2R antagonism had no effect on inflammation, intracranial 
complications, and short-term outcome in PM. This may be explained by substantial down-regulation of P2R 
subtypes expression in the brain and loss of ATP in the CSF (presumably via an increased catabolism by BMN 
and BMDM).
Materials and Methods
Ethics statement. This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals (National Research Council, USA) and with the German Animal 
Protection Act. The study protocol was approved by the Committee on the Ethics of Animal Experiments of the 
Government of Upper Bavaria (Permit Numbers: 55.2-1-54-2531-143-12).
Animal model of pneumococcal meningitis. A well-characterized mouse model was used in this 
study9,50. Briefly, adult male C57BL/6n mice were weighed and their body temperature was taken. Then, the 
mice were clinically examined and scored. Clinical scoring compromised [i] a beam balancing test, [ii] a pos-
tural reflex test, [iii] the presence of piloerection, seizures or reduced vigilance. In healthy animals, the score is 0 
points; eleven points are attributed to terminally ill animals that have to be euthanized due to ethics within the 
observation period. After clinical evaluation, bacterial meningitis was induced by i.c. injection of 20 μ l of 107 
colony forming units (cfu) per ml S. pneumoniae type 2 (D39 strain) under short term anesthesia with isoflurane. 
Controls were injected i.c. with 20 μ l phosphate-buffered saline. Next, animals were allowed to wake up and food 
and water were supplied ad libitum. At the end of each experiment, animals were weighed again, scored clinically, 
and the temperature was taken. Then, mice were anaesthetized with ketamine/xylazine and a catheter was placed 
into the cisterna magna. CSF samples were withdrawn for the determination of CSF leukocyte counts and CSF 
IL-1β or ATP levels. Subsequently, intracranial pressure (ICP) was monitored using a pressure transducer. Then, 
blood samples were taken by transcardial puncture. After deep anesthesia with ketamine/xylazin, mice were 
perfused with 15 ml ice-cold PBS containing 10 U/ml heparin. The brains were removed and frozen immediately.
Experimental groups. In order to evaluate the role of eATP in PM, C57BL6/n mice (Charles River GmbH, 
Germany) were infected and immediately thereafter treated with an intraperitoneal (i.p.) injection of 20 mg/kg 
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body weight suramin (n = 11; an non-selective P2R antagonist from Tocris Bioscience, Germany)23,51 or 50 mg/kg 
body weight brilliant blue G (n = 11; BBG, a P2X7 R antagonist from Sigma Aldrich GmbH, Germany; both dis-
solved in sterile water)20,21, respectively. In an additional experimental group, suramin was given via the intrath-
ecal route two hours before infection (n = 11; 20 mg/kg brain weight; the total brain weight was assumed to be 
0.5 gram, according to data provided by Wahlsten et al.52.). This was done since suramin was reported to penetrate 
only poorly into the brain (with the exception of the circumventricular organs that lack an intact blood-brain 
barrier)22,23. Infected mice that were injected i.p. (n = 21) with sterile water served as positive controls, whereas 
mice which were i.c. injected with PBS were used as negative controls (n = 4). In order to exclude any impact of 
the intrathecal injection procedure on the disease course, a subgroup of mice (n = 5) was intrathecally treated 
with sterile water (20 μ l; a volume corresponding to that of suramin) two hours prior to pneumococcal infection. 
In Supplemental Experiments, CSF and brain samples were collected from mice at various time points, namely 
before (n = 4), 4 h (n = 4), 16 h (n = 5), and 40 h (n = 4) after infection. These samples were used from determin-
ing CSF ATP concentrations as well as brain P2Rs mRNA expression levels.
Determination of bacterial titers in blood and brain. Cerebella were dissected and homogenized in 
sterile saline. Blood samples and cerebellar homogenates were diluted serially in sterile saline, plated on blood 
agar plates, and cultured for 24 h at 37 °C with 5% CO2.
Analysis of cerebral bleeding. Haemorrhagic spots were counted and the bleeding area was measured as 
described previously50.
Real-time RT-PCR analysis of brain P2 receptors expression. Total RNA was isolated from homog-
enized brain tissue, using the RNeasy Mini-Kit (Qiagen, Hilden, Germany) following the manufacturer’s rec-
ommendations. Reverse transcription was performed using Stratascript reverse transcriptase (Stratagene, La 
Jolla, CA) and random primers (Invitrogen, Germany). Quantitative PCR was performed with Taqman Universal 
PCR Mastermix (Applied Biosystems, Foster City, CA) and preformulated primers and probe mixes (Assay on 
Demand; Applied Biosystems). PCR conditions were 2 min at 50 °C and 10 min at 95 °C, followed by 45 cycles 
of 15 s at 95 °C and 60 °C for 1 min using a thermal cycler (iCycler; Bio-Rad, Hercules, CA). PCR amplification 
of the housekeeping gene encoding β 2-microglobulin was performed during each run for each sample to allow 
normalization between samples.
Cell culture experiments. BMDM (from C57BL6/n mice) were prepared from bone marrow cells isolated 
from femurs as described previously9. After 7 days of differentiation with macrophage-colony stimulating factor 
(M-CSF), cells were detached from the culture dish by brief accutase® treatment, washed, suspended in mac-
rophage medium (DMEM containing 1% fetal calf serum [FCS], 1% HEPES, and 10 μ g/ml penicillin plus strep-
tomycin, all from Sigma-Aldrich GmbH), counted, and seeded at a concentration of 200,000 cells per well in a 
96 well plate. BMDM were primed with 100 nM phorbol 12-myristate 13-acetate (PMA) for 24 hours. Then, the 
medium was replaced by macrophage medium, and cells were exposed to S. pneumoniae (D39 strain; at a con-
centration of 107 cfu/ml) for six hours in the absence or presence of the following compounds: suramin (10, 100, 
1000 μ M) and BBG (1, 10, 100 μ M). At the end of each experiment, cell culture supernatants were collected for 
the determination of LDH, IL-1β , and IL-6.
In Supplemental Experiments, BMDM were suspended in artificial CSF (aCSF)53 (containing 1% FCS, 0.1 g/l 
D-lactate, 0.75 g/dl D-glucose, and 10 nM ATP), and seeded at concentration of 100,000 cells per well in a 96 well 
plate. Subsequently, cells were exposed to live S. pneumoniae (D39 strain, at a concentration either of 106 cfu/ml 
or 107 cfu/ml) for 30 and 120 min in the absence or presence of 1 mM ARL67156. Thereafter, cell culture super-
natants were sampled for ATP determinations. In additional experiments, bone marrow-derived neutrophils 
(BMN) were used instead of BMDM. BMN were isolated as described previously54.
Measurement of IL-1β, IL-6, and ATP concentrations. IL-1β and IL-6 concentrations in cell cul-
ture supernatants and/or CSF samples were determined by ELISA (R&D Systems, Germany), according to the 
manufacturer’s instructions. ATP was indirectly measured with a bioluminescence assay kit (Molecular Probes, 
Oregon, USA).
Statistical analysis. The principal statistical test was one way analysis of variance and subsequent 
Student-Newman-Keuls post-hoc tests. Differences were considered significant at P < 0.05. Data are displayed 
as means ± SD.
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